IP Library Granted Patent US 12,469,040
Granted Patent B1
US 12,469,040 · App. 18/138,414 · Granted Nov 11, 2025

Method, apparatus, and computer program product for providing real-time pricing information

Inventors: Stacy McCrommon (Loganville, GA); Scott Genone (Roswell, GA); Mark Beers (Lilburn, GA); Keith Crozier (North Kingstown, RI)
Assignee: McKesson Corporation
G06Q30/0206G06Q40/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,469,040
App. No.
18/138,414
Granted
Nov 11, 2025
Kind
B1
Abstract

A method, apparatus and computer program product are provided for providing real-time or near real-time pricing information with improved efficiency. A special price may be returned in response to a prescription inquiry, and/or an alternative price obtained from stored prescription transactions. The prescription inquiry may be transmitted to a claims processor computer and/cash discount system in certain scenarios. If a response is not received within a time threshold, an estimated cost range may be determined. The real-time or near real-time pricing information is provided to a prescriber computer and may improve the efficiency of related systems, as well as prescription adherence by patients.

Claims (50)

1 . An apparatus comprising one or more processors and at least one memory including computer program code, that when executed by the one or more processors, causes the one or more processors to perform steps of:

storing a time threshold, and prescription transactions comprising prior prices paid by patients for medication;

storing a special price list comprising one or more special prices for which a medication can be purchased at one or more pharmacies;

receiving from a prescriber computer, a prescription inquiry comprising a routing indication, a patient, a pharmacy, and a prescribed medication;

accessing the prescription transactions and determining at least one alternative price for which the prescribed medication is available with at least one of one or more benefits, one or more incentives, or cash discounts;

accessing the special price list and determining based on the prescription inquiry whether a special price is available;

if a special price is available:

in an instance the special price is less than the at least one alternative price, transmitting the special price to the prescriber computer;

if: (a) the special price is not available, or (b) the special price is greater than or equal to the at least one alternative price:

transmitting, based on the routing indication, the prescription inquiry to either at least one of a claims processor computer or a cash discount system;

in an instance in which a response to the transmitted prescription inquiry is received from the claims processor computer or the cash discount system within the time threshold and the response comprises a patient pay amount, transmitting the response, comprising the patient pay amount and an indication of at least one of the claims processor computer or the cash discount system from which the response was received, to the prescriber computer; and

in an instance a response to the transmitted prescription inquiry is not received from the claims processor computer or the cash discount system within the time threshold or the response received within the time threshold lacks the patient pay amount, determining an estimated cost range for the prescribed medication based on the prescription transactions, and transmitting the estimated cost range for the prescribed medication to the prescriber computer.

2 . The apparatus according to claim 1 , wherein the special price comprises a pharmacy cash price of a generic version of the prescribed medication.

3 . The apparatus according to claim 1 , wherein the computer program code, that when executed by the one or more processors, further causes the one or more processors to perform a step of:

providing to the prescriber computer in real-time or near real-time relative to receiving the prescription inquiry from the prescriber computer, at least one of: (a) the special price, (b) the response comprising the patient pay amount, or (c) the estimated cost range.

4 . The apparatus according to claim 1 , wherein determining the estimated cost range comprises:

determining an average value based on a paid amount associated with each of the prescription transactions;

identifying a subset of the prescription transactions based on the average value; and

from the subset of prescription transactions, determining the estimated cost range of the prescribed medication based on the average value.

5 . The apparatus according to claim 1 , wherein the computer program code, that when executed by the one or more processors, further causes the one or more processors to perform steps of:

in an instance at least one of: (a) the special price is not available, or (b) the special price is greater than or equal to the at least one alternative price:

identifying the claims processor computer or the cash discount system associated with a lower patient cost than a patient cost associated with the other of the identified claims processor computer or the cash discount system according to the prescription transactions; and

transmitting the prescription inquiry to the identified claims processor computer or the identified cash discount system.

6 . The apparatus according to claim 1 , wherein the computer program code, that when executed by the at least one or more processors, causes the one or more processors to perform a step of:

applying a manufacturer paid incentive to a response from at least one of the claims processor computer or cash discount system.

7 . A computer program product comprising at least one non-transitory computer-readable storage medium having computer-executable program code instructions stored therein, that when executed by one or more processors, cause the one or more processors to perform steps of:

storing a time threshold, and prescription transactions comprising prior prices paid by patients for medication;

storing a special price list comprising one or more special prices for which a medication can be purchased at one or more pharmacies;

receiving from a prescriber computer, a prescription inquiry comprising a routing indication, a patient, a pharmacy, and a prescribed medication;

accessing the prescription transactions and determining at least one alternative price for which the prescribed medication is available with at least one of one or more benefits, one or more incentives, or cash discounts;

accessing the special price list and determining based on the prescription inquiry whether a special price is available;

if a special price is available:

in an instance the special price is less than the at least one alternative price, transmitting the special price to the prescriber computer;

if: (a) the special price is not available, or (b) the special price is greater than or equal to the at least one alternative price:

transmitting, based on the routing indication, the prescription inquiry to either at least one of a claims processor computer or a cash discount system;

in an instance in which a response to the transmitted prescription inquiry is received from the claims processor computer or the cash discount system within the time threshold and the response comprises a patient pay amount, transmitting the response, comprising the patient pay amount and an indication of at least one of the claims processor computer or the cash discount system from which the response was received, to the prescriber computer; and

in an instance a response to the transmitted prescription inquiry is not received from the claims processor computer or the cash discount system within the time threshold or the response received within the time threshold lacks the patient pay amount, determining an estimated cost range for the prescribed medication based on the prescription transactions, and transmitting the estimated cost range for the prescribed medication to the prescriber computer.

8 . The computer program product according to claim 7 , wherein the special price comprises a pharmacy cash price of a generic version of the prescribed medication.

9 . The computer program product according to claim 7 , wherein the computer-executable program code instructions, when executed by the one or more processors, further cause the one or more processors to perform a step of:

providing to the prescriber computer in real-time or near real-time relative to receiving the prescription inquiry from the prescriber computer, at least one (a) of the special price, (b) the response comprising the patient pay amount, or (c) the estimated cost range.

10 . The computer program product according to claim 7 , wherein determining the estimated cost range comprises:

determining an average value based on a paid amount associated with each of the prescription transactions;

identifying a subset of the prescription transactions based on the average value; and

from the subset of prescription transactions, determining the estimated cost range of the prescribed medication based on the average value.

11 . The computer program product according to claim 7 , wherein the computer-executable program code instructions, when executed by the one or more processors, further cause the one or more processors to perform steps of:

in an instance at least one of: (a) the special price is not available, or (b) the special price is greater than or equal to the at least one alternative price:

identifying the claims processor computer or the cash discount system associated with a lower patient cost than a patient cost associated with the other of the identified claims processor computer or the cash discount system according to the prescription transactions; and

transmitting the prescription inquiry to the identified claims processor computer or the identified cash discount system.

12 . The computer program product according to claim 7 , wherein the computer-executable program code instructions, when executed by the one or more processors, further cause the one or more processors to perform a step of:

applying a manufacturer paid incentive to a response from at least one of the claims processor computer or cash discount system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: MCCROMMON, STACY; GENONE, SCOTT; BEERS, MARK; CROZIER, KEITH
To: MCKESSON CORPORATION
Reel/Frame 063532/0162 →
Continuity (5)
Continuation In Part 17499976 · Oct 13, 2021
Continuation In Part 16832318 · Mar 27, 2020
Continuation In Part 16698752 · Nov 27, 2019
Continuation In Part 16453509 · Jun 26, 2019
Continuation In Part 16453509 · Jun 26, 2019
References Cited (400)
US 5012035A · Sartori et al. · 1991 [cited by applicant]
US 5173851A · Off et al. · 1992 [cited by applicant]
US 5595342A · McNair et al. · 1997 [cited by applicant]
US 5628530A · Thornton · 1997 [cited by applicant]
US 5726092A · Mathews et al. · 1998 [cited by applicant]
US 5757898A · Nishikawa · 1998 [cited by applicant]
US 5769228A · Wroblewski · 1998 [cited by applicant]
US 6012035A · Freeman et al. · 2000 [cited by applicant]
US 6111218A · Akers et al. · 2000 [cited by applicant]
US 6463462B1 · Smith et al. · 2002 [cited by applicant]
US 6595342B1 · Maritzen et al. · 2003 [cited by applicant]
US 6726092B2 · Goldberg et al. · 2004 [cited by applicant]
US 6757898B1 · Ilsen et al. · 2004 [cited by applicant]
US 6769228B1 · Mahar · 2004 [cited by applicant]
US 7155397B2 · Alexander et al. · 2006 [cited by applicant]
US 7192741B2 · Otte et al. · 2007 [cited by applicant]
US 7337129B1 · Lowry et al. · 2008 [cited by applicant]
US 7346768B2 · DiRienzo · 2008 [cited by applicant]
US 7409632B1 · DiRienzo · 2008 [cited by applicant]
US 7426476B2 · Munoz et al. · 2008 [cited by applicant]
US 7734483B1 · Smith et al. · 2010 [cited by applicant]
US 7783383B2 · Eliuk et al. · 2010 [cited by applicant]
US 7840424B2 · Wiley et al. · 2010 [cited by applicant]
US 7856364B1 · Wiley et al. · 2010 [cited by applicant]
US 7912741B1 · Pinsonneault · 2011 [cited by applicant]
US 7921021B1 · Newman · 2011 [cited by applicant]
US 8036913B1 · Pinsonneault et al. · 2011 [cited by applicant]
US 8036914B1 · Pinsonneault · 2011 [cited by applicant]
US 8036918B1 · Pinsonneault · 2011 [cited by applicant]
US 8050943B1 · Wiley et al. · 2011 [cited by applicant]
US 8060379B1 · Pinsonneault et al. · 2011 [cited by applicant]
US 8126743B1 · Wilk · 2012 [cited by applicant]
US 8326773B1 · Bellamy · 2012 [cited by applicant]
US 8346571B2 · Kalies, Jr. · 2013 [cited by examiner]
US 8412537B1 · Fenton et al. · 2013 [cited by applicant]
US 8442847B1 · Shrivastava · 2013 [cited by applicant]
US 8489415B1 · Ringold · 2013 [cited by applicant]
US 8521557B1 · Ringold et al. · 2013 [cited by applicant]
US 8560340B1 · Ringold · 2013 [cited by applicant]
US 8639523B1 · Pinsonneault · 2014 [cited by applicant]
US 8645162B2 · Boerger et al. · 2014 [cited by applicant]
US 8671018B2 · Thomas et al. · 2014 [cited by applicant]
US 8712797B1 · Bezdek et al. · 2014 [cited by applicant]
US 8738399B1 · Abou Nader et al. · 2014 [cited by applicant]
US 8786650B1 · Eller et al. · 2014 [cited by applicant]
US 8799018B1 · Rea et al. · 2014 [cited by applicant]
US 8984059B2 · Johnson · 2015 [cited by applicant]
US 9026507B2 · Shraim et al. · 2015 [cited by applicant]
US 9100793B2 · Johnson · 2015 [cited by applicant]
US 9171322B2 · Spievak et al. · 2015 [cited by applicant]
US 9356947B2 · Shraim et al. · 2016 [cited by applicant]
US 9760871B1 · Pourfallah et al. · 2017 [cited by applicant]
US 9779129B1 · Lequeux · 2017 [cited by applicant]
US 9786023B2 · Cohan et al. · 2017 [cited by applicant]
US 10109027B1 · Stack · 2018 [cited by applicant]
US 10157262B1 · Pinsonneault · 2018 [cited by applicant]
US 10331855B1 · Bratton et al. · 2019 [cited by applicant]
US 10417380B1 · Kaye et al. · 2019 [cited by applicant]
US 10489552B2 · Pinsonneault · 2019 [cited by applicant]
US 10496793B1 · Lawrence et al. · 2019 [cited by applicant]
US 10565656B1 · Pinsonneault et al. · 2020 [cited by applicant]
US 10606984B1 · Kaye et al. · 2020 [cited by applicant]
US 10616146B1 · Hopkins et al. · 2020 [cited by applicant]
US 10628797B2 · Shraim et al. · 2020 [cited by applicant]
US 10642812B1 · Hopkins et al. · 2020 [cited by applicant]
US 10713694B1 · Harris et al. · 2020 [cited by applicant]
US 10747848B2 · Guinan · 2020 [cited by applicant]
US 10778618B2 · Karnin et al. · 2020 [cited by applicant]
US 10862832B1 · Harris · 2020 [cited by applicant]
US 10924545B2 · Momchilov et al. · 2021 [cited by applicant]
US 10924585B1 · Harris et al. · 2021 [cited by applicant]
US 10929932B1 · Golden et al. · 2021 [cited by applicant]
US 10978198B1 · Pinsonneault · 2021 [cited by applicant]
US 10999224B1 · Frechen et al. · 2021 [cited by applicant]
US 11043293B1 · Salzbrenner · 2021 [cited by applicant]
US 11170394B1 · Macinski · 2021 [cited by applicant]
US 11398992B1 · Frechen et al. · 2022 [cited by applicant]
US 11418468B1 · Harris · 2022 [cited by applicant]
US 11443835B1 · Gangaikondan-Iyer et al. · 2022 [cited by applicant]
US 11508471B1 · Anselmi et al. · 2022 [cited by applicant]
US 11514137B1 · Kaye et al. · 2022 [cited by applicant]
US 11562437B1 · Hopkins et al. · 2023 [cited by applicant]
US 11587657B2 · Hopkins et al. · 2023 [cited by applicant]
US 11610240B1 · Burdine · 2023 [cited by applicant]
US 11636548B1 · Hopkins et al. · 2023 [cited by applicant]
US 11640618B1 · Burdine · 2023 [cited by applicant]
US 20010029483A1 · Schultz et al. · 2001 [cited by applicant]
US 20010037216A1 · Oscar et al. · 2001 [cited by applicant]
US 20010039589A1 · Aho et al. · 2001 [cited by applicant]
US 20010056359A1 · Abreu · 2001 [cited by applicant]
US 20020002495A1 · Ullman · 2002 [cited by applicant]
US 20020004812A1 · Motoyama · 2002 [cited by applicant]
US 20020032582A1 · Feeney et al. · 2002 [cited by applicant]
US 20020032583A1 · Joao · 2002 [cited by applicant]
US 20020035484A1 · McCormick · 2002 [cited by applicant]
US 20020087583A1 · Morgan et al. · 2002 [cited by applicant]
US 20020111832A1 · Judge · 2002 [cited by applicant]
US 20020133379A1 · Lewis et al. · 2002 [cited by applicant]
US 20020143579A1 · Docherty et al. · 2002 [cited by applicant]
US 20020147614A1 · Doerr et al. · 2002 [cited by applicant]
US 20020188552A1 · Kavounas et al. · 2002 [cited by applicant]
US 20020198831A1 · Patricelli et al. · 2002 [cited by applicant]
US 20030009367A1 · Morrison · 2003 [cited by applicant]
US 20030050796A1 · Baldwin · 2003 [cited by applicant]
US 20030050799A1 · Jay et al. · 2003 [cited by applicant]
US 20030069760A1 · Gelber · 2003 [cited by applicant]
US 20030074234A1 · Stasny · 2003 [cited by applicant]
US 20030097310A1 · Ono et al. · 2003 [cited by applicant]
US 20030130875A1 · Hawash et al. · 2003 [cited by applicant]
US 20030149625A1 · Leonardi et al. · 2003 [cited by applicant]
US 20030154163A1 · Phillips et al. · 2003 [cited by applicant]
US 20030172008A1 · Hage et al. · 2003 [cited by applicant]
US 20030187690A1 · Miller · 2003 [cited by applicant]
US 20030229540A1 · Algiene · 2003 [cited by applicant]
US 20030236747A1 · Sager · 2003 [cited by applicant]
US 20040006490A1 · Gingrich et al. · 2004 [cited by applicant]
US 20040039599A1 · Fralic · 2004 [cited by applicant]
US 20040054685A1 · Rahn et al. · 2004 [cited by applicant]
US 20040059607A1 · Ball et al. · 2004 [cited by applicant]
US 20040073456A1 · Gottlieb et al. · 2004 [cited by applicant]
US 20040073457A1 · Kalies · 2004 [cited by applicant]
US 20040078222A1 · Khan et al. · 2004 [cited by applicant]
US 20040078234A1 · Tallal, Jr. · 2004 [cited by applicant]
US 20040088187A1 · Chudy et al. · 2004 [cited by applicant]
US 20040103062A1 · Wood et al. · 2004 [cited by applicant]
US 20040117323A1 · Mindala · 2004 [cited by applicant]
US 20040148198A1 · Kalies · 2004 [cited by applicant]
US 20040153336A1 · Virdee et al. · 2004 [cited by applicant]
US 20040199545A1 · Wagner et al. · 2004 [cited by applicant]
US 20040236630A1 · Kost et al. · 2004 [cited by applicant]
US 20040249745A1 · Baaren · 2004 [cited by applicant]
US 20050015280A1 · Gabel et al. · 2005 [cited by applicant]
US 20050060201A1 · Connely, III et al. · 2005 [cited by applicant]
US 20050065821A1 · Kalies, Jr. · 2005 [cited by applicant]
US 20050075932A1 · Mankoff · 2005 [cited by applicant]
US 20050080692A1 · Padam et al. · 2005 [cited by applicant]
US 20050102169A1 · Wilson · 2005 [cited by applicant]
US 20050154627A1 · Zuzek et al. · 2005 [cited by applicant]
US 20050187793A1 · Myles · 2005 [cited by applicant]
US 20050197862A1 · Paterson et al. · 2005 [cited by applicant]
US 20050240442A1 · Lapsker et al. · 2005 [cited by applicant]
US 20050240473A1 · Ayers, Jr. et al. · 2005 [cited by applicant]
US 20050261939A1 · Augspurger et al. · 2005 [cited by applicant]
US 20050288972A1 · Marvin et al. · 2005 [cited by applicant]
US 20060020514A1 · Yered · 2006 [cited by applicant]
US 20060026041A1 · Ullman · 2006 [cited by applicant]
US 20060036470A1 · Oaks · 2006 [cited by applicant]
US 20060085231A1 · Brofman · 2006 [cited by applicant]
US 20060085385A1 · Foster et al. · 2006 [cited by applicant]
US 20060113376A1 · Reed et al. · 2006 [cited by applicant]
US 20060149595A1 · Williams et al. · 2006 [cited by applicant]
US 20060149784A1 · Tholl et al. · 2006 [cited by applicant]
US 20060184391A1 · Barre et al. · 2006 [cited by applicant]
US 20060212318A1 · Dooley · 2006 [cited by applicant]
US 20060212345A1 · Soza et al. · 2006 [cited by applicant]
US 20060224414A1 · Astrup et al. · 2006 [cited by applicant]
US 20060224417A1 · Werner · 2006 [cited by applicant]
US 20060224443A1 · Soza et al. · 2006 [cited by applicant]
US 20060235747A1 · Hammond et al. · 2006 [cited by applicant]
US 20060259363A1 · Jhetam et al. · 2006 [cited by applicant]
US 20070005402A1 · Kennedy et al. · 2007 [cited by applicant]
US 20070033137A1 · Provost et al. · 2007 [cited by applicant]
US 20070043589A1 · Warren et al. · 2007 [cited by applicant]
US 20070043595A1 · Pederson · 2007 [cited by applicant]
US 20070050209A1 · Yered · 2007 [cited by applicant]
US 20070050210A1 · Wiley, II · 2007 [cited by applicant]
US 20070067186A1 · Brenner et al. · 2007 [cited by applicant]
US 20070094133A1 · Anandarao et al. · 2007 [cited by applicant]
US 20070108053A1 · Cramer et al. · 2007 [cited by applicant]
US 20070136100A1 · Daugherty et al. · 2007 [cited by applicant]
US 20070162303A1 · Wiley et al. · 2007 [cited by applicant]
US 20070168228A1 · Lawless · 2007 [cited by applicant]
US 20070185799A1 · Harrison et al. · 2007 [cited by applicant]
US 20070191985A1 · Bain · 2007 [cited by applicant]
US 20070194352A1 · Han · 2007 [cited by applicant]
US 20070202886A1 · Dhebri et al. · 2007 [cited by applicant]
US 20070204043A1 · Espinosa et al. · 2007 [cited by applicant]
US 20070219813A1 · Moore · 2007 [cited by applicant]
US 20070233525A1 · Boyle · 2007 [cited by applicant]
US 20070233526A1 · Hoffman et al. · 2007 [cited by applicant]
US 20070239493A1 · Sweetland et al. · 2007 [cited by applicant]
US 20070250341A1 · Howe et al. · 2007 [cited by applicant]
US 20070260750A1 · Feied et al. · 2007 [cited by applicant]
US 20070276697A1 · Wiley et al. · 2007 [cited by applicant]
US 20070294765A1 · Rihn et al. · 2007 [cited by applicant]
US 20070299915A1 · Shraim et al. · 2007 [cited by applicant]
US 20080033750A1 · Swiss et al. · 2008 [cited by applicant]
US 20080103836A1 · Park et al. · 2008 [cited by applicant]
US 20080112411A1 · Stafford et al. · 2008 [cited by applicant]
US 20080152107A1 · Mendiola · 2008 [cited by applicant]
US 20080183492A1 · Warren et al. · 2008 [cited by applicant]
US 20080215361A1 · Nunnari et al. · 2008 [cited by applicant]
US 20080262948A1 · Grady et al. · 2008 [cited by applicant]
US 20090006141A1 · Karr · 2009 [cited by applicant]
US 20090030719A1 · Nadas et al. · 2009 [cited by applicant]
US 20090064330A1 · Shraim et al. · 2009 [cited by applicant]
US 20090083064A1 · Mahinda · 2009 [cited by applicant]
US 20090094051A1 · Ard et al. · 2009 [cited by applicant]
US 20090100099A1 · Buckwalter · 2009 [cited by applicant]
US 20090106313A1 · Boldyga · 2009 [cited by applicant]
US 20090112707A1 · Weiss et al. · 2009 [cited by applicant]
US 20090198510A1 · Ditto · 2009 [cited by applicant]
US 20090204477A1 · Urso · 2009 [cited by applicant]
US 20090287558A1 · Seth et al. · 2009 [cited by applicant]
US 20090313112A1 · Champ et al. · 2009 [cited by applicant]
US 20090327363A1 · Cullen et al. · 2009 [cited by applicant]
US 20100030667A1 · Chudy et al. · 2010 [cited by applicant]
US 20100070298A1 · Kalies · 2010 [cited by applicant]
US 20100144259A1 · Allexon et al. · 2010 [cited by applicant]
US 20100145730A1 · Abreu · 2010 [cited by applicant]
US 20100161353A1 · Mayaud · 2010 [cited by applicant]
US 20100217622A1 · Brown et al. · 2010 [cited by applicant]
US 20100285821A1 · Smeeding et al. · 2010 [cited by applicant]
US 20100287001A1 · Pearce et al. · 2010 [cited by applicant]
US 20100293236A1 · Wisner et al. · 2010 [cited by applicant]
US 20110015978A1 · Welch, Jr. · 2011 [cited by applicant]
US 20110112871A1 · Simonowski et al. · 2011 [cited by applicant]
US 20110161109A1 · Pinsonneault et al. · 2011 [cited by applicant]
US 20110196697A1 · Akers · 2011 [cited by applicant]
US 20110288925A1 · Thomas et al. · 2011 [cited by applicant]
US 20120053958A1 · Marshall et al. · 2012 [cited by applicant]
US 20120109839A1 · Anderson et al. · 2012 [cited by applicant]
US 20120136809A1 · Cannata et al. · 2012 [cited by applicant]
US 20120143627A1 · Ruben et al. · 2012 [cited by applicant]
US 20120166268A1 · Griffiths · 2012 [cited by applicant]
US 20120179481A1 · Patel et al. · 2012 [cited by applicant]
US 20120185263A1 · Emert · 2012 [cited by applicant]
US 20120185264A1 · Demogenes et al. · 2012 [cited by applicant]
US 20120253829A1 · John et al. · 2012 [cited by applicant]
US 20120253830A1 · John · 2012 [cited by examiner]
US 20120253831A1 · John et al. · 2012 [cited by applicant]
US 20120253832A1 · John et al. · 2012 [cited by applicant]
US 20120253833A1 · John et al. · 2012 [cited by applicant]
US 20120253846A1 · John et al. · 2012 [cited by applicant]
US 20120265591A1 · Hwang · 2012 [cited by applicant]
US 20120323608A1 · Herzlinger · 2012 [cited by applicant]
US 20130041968A1 · Cohen et al. · 2013 [cited by applicant]
US 20130046610A1 · Abraham · 2013 [cited by applicant]
US 20130103602A1 · Melnick et al. · 2013 [cited by applicant]
US 20130144715A1 · Kranzley et al. · 2013 [cited by applicant]
US 20130179180A1 · Patra · 2013 [cited by applicant]
US 20130191147A1 · Harrell · 2013 [cited by examiner]
US 20130197980A1 · Lerner et al. · 2013 [cited by applicant]
US 20130246082A1 · Brylawski et al. · 2013 [cited by applicant]
US 20130311389A1 · Kaehler et al. · 2013 [cited by applicant]
US 20140039911A1 · Iyer · 2014 [cited by applicant]
US 20140088985A1 · Grant et al. · 2014 [cited by applicant]
US 20140214435A1 · Previdi · 2014 [cited by applicant]
US 20140249861A1 · Gamble et al. · 2014 [cited by applicant]
US 20140249864A1 · Sultan et al. · 2014 [cited by applicant]
US 20140278448A1 · Sadeghi et al. · 2014 [cited by applicant]
US 20140278456A1 · Milosevich et al. · 2014 [cited by applicant]
US 20140278531A1 · Gupta · 2014 [cited by applicant]
US 20150032465A1 · Sundar et al. · 2015 [cited by applicant]
US 20150088557A1 · Huynh et al. · 2015 [cited by applicant]
US 20150142479A1 · Porter et al. · 2015 [cited by applicant]
US 20150149197A1 · Guinan · 2015 [cited by applicant]
US 20150154565A1 · Kaehler et al. · 2015 [cited by applicant]
US 20150154588A1 · Purves et al. · 2015 [cited by applicant]
US 20150195224A1 · Karnin et al. · 2015 [cited by applicant]
US 20150213195A1 · Blechman · 2015 [cited by applicant]
US 20150234991A1 · Pinsonneault · 2015 [cited by applicant]
US 20150235177A1 · Shraim et al. · 2015 [cited by applicant]
US 20150269695A1 · Pinsonneault et al. · 2015 [cited by applicant]
US 20150278472A1 · King · 2015 [cited by applicant]
US 20150332422A1 · Gilmartin · 2015 [cited by applicant]
US 20150371000A1 · Pinsonneault · 2015 [cited by applicant]
US 20160012465A1 · Sharp · 2016 [cited by applicant]
US 20160103978A1 · Stong · 2016 [cited by applicant]
US 20160140593A1 · Smeeding et al. · 2016 [cited by applicant]
US 20160213512A1 · Palanker et al. · 2016 [cited by applicant]
US 20160267544A1 · Flood et al. · 2016 [cited by applicant]
US 20160267545A1 · Glass et al. · 2016 [cited by applicant]
US 20160307195A1 · Cantwell et al. · 2016 [cited by applicant]
US 20160321406A1 · Timmerman et al. · 2016 [cited by applicant]
US 20160321410A1 · Timmerman et al. · 2016 [cited by applicant]
US 20160358142A1 · Hillen · 2016 [cited by applicant]
US 20160358293A1 · Berger et al. · 2016 [cited by applicant]
US 20160359795A1 · Fehling · 2016 [cited by applicant]
US 20170034087A1 · Borenstein et al. · 2017 [cited by applicant]
US 20170039331A1 · Bezdek · 2017 [cited by examiner]
US 20170220768A1 · Tanner, Jr. et al. · 2017 [cited by applicant]
US 20170255759A1 · McGrath · 2017 [cited by applicant]
US 20170323295A1 · Kranzley et al. · 2017 [cited by applicant]
US 20170324695A1 · Fischer et al. · 2017 [cited by applicant]
US 20170329922A1 · Eberting et al. · 2017 [cited by applicant]
US 20180012244A1 · Leonardi · 2018 [cited by applicant]
US 20180075212A1 · Kubey · 2018 [cited by examiner]
US 20180075215A1 · Loiacoono · 2018 [cited by applicant]
US 20180366810A1 · Nero et al. · 2018 [cited by applicant]
US 20190095582A1 · Waits · 2019 [cited by applicant]
US 20190213212A1 · Adato et al. · 2019 [cited by applicant]
US 20190252049A1 · Fotsch et al. · 2019 [cited by applicant]
US 20190385733A1 · Kaye et al. · 2019 [cited by applicant]
US 20190385734A1 · Pinsonneault · 2019 [cited by applicant]
US 20200105392A1 · Karkazis et al. · 2020 [cited by applicant]
US 20200372988A1 · Bezdek et al. · 2020 [cited by applicant]
US 20210319887A1 · Derrick, Jr. et al. · 2021 [cited by applicant]
US 20210374872A1 · Stewart et al. · 2021 [cited by applicant]
US 20210374876A1 · Cedergreen · 2021 [cited by applicant]
AU 2003243327A · 2003 [cited by applicant]
CA 2482370A1 · 2006 [cited by applicant]
CA 2792252A1 · 2013 [cited by applicant]
CA 2810686A1 · 2013 [cited by applicant]
CN 102362778 · 2012 [cited by applicant]
KR 100755440 · 2007 [cited by applicant]
KR 100793852 · 2008 [cited by applicant]
KR 101038074 · 2011 [cited by applicant]
KR 101101692 · 2011 [cited by applicant]
KR 20110138108 · 2011 [cited by applicant]
KR 20110138572 · 2011 [cited by applicant]
KR 101154858 · 2012 [cited by applicant]
WO WO1991006917A1 · 1991 [cited by applicant]
WO WO1995003569A2 · 1995 [cited by applicant]
WO WO1997025682A1 · 1997 [cited by applicant]
WO WO1998050871A1 · 1998 [cited by applicant]
WO WO2000039737A1 · 2000 [cited by applicant]
WO WO2003098401A2 · 2003 [cited by applicant]
WO WO2007025295A2 · 2007 [cited by applicant]
WO WO2007094772A1 · 2007 [cited by applicant]
WO WO2008092109A2 · 2008 [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 16/816,460, dated Aug. 10, 2023, 14 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/144,426, dated Jul. 13, 2023, 17 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/158,118, dated Jul. 13, 2023, 18 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/705,919, dated Aug. 17, 2023, 68 pages, US. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 17/162,461, dated Aug. 24, 2023, 2 pages, US. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 16/816,460, dated Aug. 1, 2024, 3 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 17/162,461, dated Aug. 19, 2024, 2 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 18/098,150, dated Aug. 27, 2024, 61 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Interview Summary received for U.S. Appl. No. 17/675,616, dated Aug. 15, 2024,8 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/846,373, dated Apr. 5, 2024, 76 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/674,366, dated Jun. 5, 2024, 54 pages, US. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/162,461, dated Jun. 4, 2024, 38 pages, US. [cited by applicant]
Liu, Shiyong, et al., “Evaluating Cost-Effectiveness of Treatment Options for Diabetes Patients Using System Dynamics Modeling”, Proceeding of the 2018 Winter Simulation Conference (WSC), Dec. 9-12, 2018, pp. 2577-2588,… [cited by applicant]
Tiriveedhi, V., “Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis”, Journal of Personalized Medicine, Nov. 5, 2018, 11 pages, vol. 8, No. 36, MDPI, Switzerland. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 17/705,919, dated Sep. 3, 2024, 13 pages, USA. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 17/675,616, dated Sep. 25, 2024, 21 pages, USA. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 17/676,437, dated Sep. 25, 2024, 20 pages, USA. [cited by applicant]
United States Patent and Trademark Office, Examiner Interview Summary received for U.S. Appl. No. 18/098,150, dated Nov. 18, 2024, 3 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 16/816,460, dated Nov. 21, 2024, 28 pages, US. [cited by applicant]
United States Patent and Trademark Office, Examiner Interview Summary received for U.S. Appl. No. 17/175,939, dated Dec. 3, 2024, 2 pages, US. [cited by applicant]
Coase, R. H., “The Nature of the Firm”, Economica, Nov. 1937, pp. 386-405, vol. 4, No. 16, Blackwell Publishing for London School of Economics and Political Science, retrieved from the Internet at http://www.jstor.org/s… [cited by applicant]
Gemmill, Marin, “The price elasticity of demand for prescription drugs: An exploration of demand in different settings”, Doctor of Philosophy Thesis submitted to the London School of Economics and Political Science, Jan… [cited by applicant]
United States Patent and Trademark Office, Advisory Action and Examiner-Initiated Interview Summary received for U.S. Appl. No. 17/705,919, dated Jun. 25, 2024, 33 pages, US. [cited by applicant]
United States Patent and Trademark Office, Examiner's Answer received for U.S. Appl. No. 16/867,286, dated Jun. 28, 2024, 9 pages, US. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/144,426, dated Jul. 18, 2024, 19 pages, US. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/158,118, dated Jul. 18, 2024, 22 pages, US. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 17/846,373, dated Jul. 25, 2024, 16 pages, US. [cited by applicant]
Bowman, Michelle, et al., “Risk Assessment of Pharmacies & Electronic Prescriptions,” 2019 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining (ASONAM), Aug. 27-30, 2019, pp. 641-644, Va… [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 16/816,460, dated May 3, 2024, 22 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/675,616, dated May 8, 2024, 74 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/676,437, dated May 9, 2024, 73 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 16/867,286, dated Sep. 19, 2023, 16 pages, US. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 16/816,460, dated Oct. 19, 2023, 3 pages, US. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/162,461, dated Oct. 19, 2023, 25 pages, US. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 17/144,426, dated Mar. 21, 2024, 5 pages. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 17/674,366, dated Mar. 22, 2024, 6 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/705,919, dated Feb. 28, 2024, 61 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/175,939, dated Mar. 1, 2024, 24 pages. [cited by applicant]
United States Patent and Trademark Office, Examiner Interview Summary received for U.S. Appl. No. 17/144,426, dated Oct. 22, 2024,8 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Examiner Interview Summary received for U.S. Appl. No. 17/158,118, dated Oct. 22, 2024,8 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/501,532, dated Oct. 17, 2024, 37 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/499,976, dated Oct. 1, 2024, 79 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/175,939, dated Oct. 24, 2024, 17 pages, U.S. [cited by applicant]
U.S. Appl. No. 16/816,460, “Adaptive System and Method for Adjudicating Claims to Reduce Member Responsibility”, Unpublished (Filing Date Mar. 12, 2020), (Michael Rea, Inventor), (RC Savings, LLC, Assignee). [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 16/816,460, dated Mar. 3, 2023, 14 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/162,461, dated May 19, 2023, 23 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Advisory Action received for U.S. Appl. No. 17/158,118, dated May 26, 2023, 5 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received for U.S. Appl. No. 17/674,366, dated Jun. 6, 2023, 75 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Miscellaneous Office Action, Restarting Period, received for U.S. Appl. No. 17/175,939, dated Jun. 14, 2023, 23 pages, U.S. [cited by applicant]
Viswanthan, Meera, et al., “Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United States,” Annals of Internal Medicine, Dec. 4, 2012, retrieved from the Internet at <http… [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/144,426, dated Dec. 19, 2024, 22 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/158,118, dated Dec. 19, 2024, 24 pages, US. [cited by applicant]
“Pharmacy Reject Codes” NCPDP, 5 pages. [cited by applicant]
“St. Vincent's first to use Birmingham startup's information system.” The Birmingham News [Online] Apr. 11, 2005. URL: http://www.awarix.com. [cited by applicant]
“St. Vincent's is Digital Flagship” D. Lockridge; Birmingham Medical News [Online] Sep. 2005. [cited by applicant]
“Two automatic identification technology, neither new in the sense if being recent developments . . . ” Patient Safety & Quality Healthcare [Online] Aug. 2005_ URL: http://www_awarix.com. [cited by applicant]
Advisory Action for U.S. Appl. No. 14/193,294 mailed Nov. 9, 2017, 3 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/085,166 dated Apr. 11, 2019, 4 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/085,166 dated Apr. 29, 2020, 3 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/137,371 mailed Feb. 25, 2019, 5 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/427,746 mailed Jul. 2, 2019, 2 pages. [cited by applicant]
Advisory Action received for U.S. Appl. No. 15/085,166, dated Jan. 29, 2021, 3 pages, US. [cited by applicant]
Almaro, Moshe; “Recovery and Reuse of Unused Prescription Drugs” MIT What Matters: Aug. 2005. [cited by applicant]
American Hospital Association, “Drug Price Proposals”, dated Apr. 2019, retrieved from the Internet at <URL: https://www.aha.org/system/files/media/file/2019/04/aha-drug-policy-recommendations_2.pdf>, 8 pages. [cited by applicant]
American Society of Health-System Pharmacists (ASHP), “Is Prescribing the Next Step in the Evolution of Pharmacy?” May 15, 2012. [cited by applicant]
Anonymous, ACS to Demonstrate Electronic Health Record Solution Suite at MMIS 2007 Conference; EHR Tools Consolidate Data, Provide Useful Information at the Point of Care for Medicaid Providers, Payers, and Patients, PR… [cited by applicant]
Anonymous, Medic; On-line Goes In-House, Chain Store Age Executive, Jan. 1987, vol. 63, Issue 1, USA; Abstract only. [cited by applicant]
Anonymous, Pharmacy Industry Leaders Launch Firm to Supply Real-Time Data, PR Newswire, Jul. 30, 2001, p. 1, New York, NY, USA. [cited by applicant]
Anonymous, TechRx Announces Successful Beta Deployment of T-Rex. PR Newswire. May 13, 2002. [cited by applicant]
California Health Care Foundation, “When the Price Is Not Right: State Options on Prescription Drug Pricing”, dated Jun. 2016, retrieved from the Internet at: <URL: https://www.chcf.org/wp-content/uploads/2017/12/PDF-Wh… [cited by applicant]
Cepeda, Maria Soledad, et al., “Quantification of missing prescriptions in commercial claims databases : results of a cohort study.”, Pharmacoepidemiology and Drug Safety, Apr. 2017, pp. 386-392, vol. 26, Epub Jan. 25, … [cited by applicant]
Chu, Kuan-Yu, et al., “Incremental analysis of the reengineering of an outpatient billing process: an empirical study in a public hospital”, BMC Health Services Research, Jun. 13, 2013, vol. 13, No. 215, 8 pages, BioMed… [cited by applicant]
CMS Updates Drug Dashboards with Prescription Drug Pricing and Spending Data, Data, Medicare Part D, Prescription drugs (Mar. 14, 2019). [cited by applicant]
Consalvo, Bob; “City of Boston in the City Council” hearing notice, Dec. 6, 2006. [cited by applicant]
Coping with Information Overload. The News Source for Healthcare Information Technology [Online] Nov. 2004. URL: http://www.awarix.com. [cited by applicant]
Decision to Grant European Patent Application No. 13809457.8 dated May 18, 2017. [cited by applicant]
Dubois, Robert W., “Rx Drug Costs: List Prices Versus Net Prices and the Importance of Staying Within the Data”, Health Affairs Blog, Mar. 2019, 7 pages. [cited by applicant]
Examiner's Answer for U.S. Appl. No. 14/145,027 mailed Sep. 7, 2016, 27 pages. [cited by applicant]
Extended European Search Report for European Application No. 13809457.8 dated Apr. 15, 2016, 6 pages. [cited by applicant]